Skip to main content
TipRanks
Go Ultimate75% OFF

Revive Therapeutics (RVVTF) Stock Statistics & Valuation Metrics

58 Followers

Total Valuation

Revive Therapeutics has a market cap or net worth of $4.67M. The enterprise value is $15.30M.

Market Cap
$4.67M
Enterprise Value
$15.30M

Share Statistics

Revive Therapeutics has 444,613,950 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
444,613,950
Owned by Insiders
―
Owned by Institutions
<0.01%

Financial Efficiency

Revive Therapeutics’s return on equity (ROE) is 0.25 and return on invested capital (ROIC) is 26.77%.

Return on Equity (ROE)
0.25
Return on Assets (ROA)
-3.61
Return on Invested Capital (ROIC)
26.77%
Return on Capital Employed (ROCE)
0.27
Revenue Per Employee
0
Profits Per Employee
-511.82K
Employee Count
2
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Revive Therapeutics is -12.50. Revive Therapeutics’s PEG ratio is -0.11.

PE Ratio
-12.50
PS Ratio
0.00
PB Ratio
-1.63
Price to FCF
-42.07
Price to Operating Cash Flow
-41.22
PEG Ratio
-0.11

Income Statement

In the last 12 months, Revive Therapeutics had revenue of 0 and earned -1.02M in profits. Earnings per share was -0.00.

Revenue
0
Gross Profit
-189
Operating Income
-1.05M
Pretax Income
-1.02M
Net Income
-1.02M
EBITDA
-1.05M
Earnings Per Share (EPS)
-0.00

Cash Flow

In the last 12 months, operating cash flow was -158.53K and capital expenditures 0, giving a free cash flow of -158.53K billion.

Operating Cash Flow
-158.53K
Free Cash Flow
-158.53K
Free Cash Flow per Share
-0.00

Dividends & Yields

Revive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-2.38%
Earnings Yield
-15.66%

Stock Price Statistics

Beta
-1.78
52-Week Price Change
20.00%
50-Day Moving Average
0.02
200-Day Moving Average
0.02
Relative Strength Index (RSI)
41.12
Average Volume (3m)
188.12K

Important Dates

Revive Therapeutics upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).

Last Earnings Date
Oct 28, 2026
Next Earnings Date
Nov 27, 2026
Ex-Dividend Date
―

Financial Position

Revive Therapeutics as a current ratio of 0.04, with Debt / Equity ratio of 0.00%

Current Ratio
0.04
Quick Ratio
0.04
Debt to Market Cap
0.00
Net Debt to EBITDA
0.01
Interest Coverage Ratio
-91.54

Taxes

In the past 12 months, Revive Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Revive Therapeutics EV to EBITDA ratio is -6.31, with an EV/FCF ratio of -41.98.

EV to Sales
0.00
EV to EBITDA
-6.31
EV to Free Cash Flow
-41.98
EV to Operating Cash Flow
-41.98

Balance Sheet

Revive Therapeutics has $14.83K in cash and marketable securities with $0.00 in debt, giving a net cash position of $14.83K billion.

Cash & Marketable Securities
$14.83K
Total Debt
$0.00
Net Cash
$14.83K
Net Cash Per Share
$0.00
Tangible Book Value Per Share
-$0.01

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Revive Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
91.01%